Ranbaxy Laboratories Limited has received final approval in Canada to manufacture and market Ran-Amlodipine tablets 5 and 10mg (amlodipine basylate tablets) from health Canada, Therapeutic Products Directorate (TPD).
Total generic market size of amlodipine besylate tablets in Canada is $456 million ($CAD). Ran-Amlodipine tablets are indicated and employed as an antihypertensive-antianginal agent.
"We look forward to marketing both strengths of Ran-Amlodipine tablets at an affordable price that will be beneficial to both the Canadian healthcare system and most importantly, to Canadian patients. It should be noted that we have developed this dosage through the scientific skills and talents within our parent company, Ranbaxy Laboratories, Gurgaon, India and will manufacture product at Ohm Laboratories. Our North American manufacturing facility located in New Brunswick, New Jersey. Product will be offered to all classes of trade soon. We expect to start to gain formulary inclusions within a matter of weeks," said Paul Drake, president, Ranbaxy Pharmaceuticals-Canada Inc (RPCI).
RPCI, based in Mississauga, Ontario, Canada, is a wholly-owned subsidiary of Ranbaxy Laboratories Limited, India's largest pharma company. RPCI is engaged in sale and distribution of generic prescription products in the Canadian healthcare system.